ProfileGDS5678 / 1433593_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 83% 84% 84% 86% 86% 85% 86% 82% 86% 85% 83% 80% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0737283
GSM967853U87-EV human glioblastoma xenograft - Control 26.1488883
GSM967854U87-EV human glioblastoma xenograft - Control 36.2009384
GSM967855U87-EV human glioblastoma xenograft - Control 46.3897984
GSM967856U87-EV human glioblastoma xenograft - Control 56.552786
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2758186
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1487385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.4144686
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9552682
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5029886
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3424385
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.1896883
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.582480
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0353183